Skip to main content

Table 3 Comparison of 2-year outcomes according to donor HLA matching, disease status, and use of in vivo T cell depletion

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

Disease status Patients group and p value RI NRM LFS OS cGVHD Extensive
cGVHD
All 10/10 30.1 % [28.2–32.1] 24.2 % [16.4–32.9] 45.6 % [43.5–47.7] 50.6 % [48.5–52.8] 35.0 % [32.9–37.2] 17.1 % [15.4–18.9]
  9/10 32.5 % [28.9–36.3] 31.6 % [23–40.5] 35.8 % [32–39.7] 41.3 % [37.3–45.3] 35.1 % [31.2–39] 15.2 % [12.3–18.5]
  8/10 24.2 % [16.4–32.9] 35.5 % [26.6–44.4] 40.3 % [30.6–50] 43.5 % [33.6–53.3] 44.4 % [33.6–54.6] 26.1 % [16.8–36.4]
  p value 0.152 0.002 0.0001 0.0001 0.138 0.047
CR1 10/10 24.8 % [22.4–27.3] 22.5 % [11.6–35.7] 52.6 % [49.7–55.5] 56.7 % [53.8–59.6] 37.6 % [34.7–40.5] 18.1 % [15.8–20.5]
  9/10 31.6 % [26.3–37.2] 26.8 % [14.8–40.2] 41.6 % [35.7–47.5] 46.1 % [40.1–52.2] 35.9 % [30–41.9] 13 % [9.1–17.7]
  8/10 17.7 % [8.1–30.2] 33.3 % [20.4–46.8] 49% [34.3–63.7] 50.2 % % [35.2–65.1] 43.4 % [26.4–59.2] 22.1 % [9.5–37.9]
  p value 0.010 0.136 0.005 0.005 0.641 0.107
≥CR2 10/10 32.6 % [28.2–37.1] 24.1 % [8.7–43.5] 43.3 % [38.5–48.1] 50.1 % [45.3–55] 35 % [30.3–39.7] 13.9 % [10.6–17.7]
  9/10 26.3 % [19.5–33.5] 32.5 % [14.6–51.8] 41.2 % [33.3–49.2] 48 % [40–56.1] 34.7 % [26.8–42.7] 18.3 % [12.1–25.6]
  8/10 22.4 % [7.7–41.7] 24.6 % [9.1–44.1] 53 % [31.3–74.7] 62 % [40.8–83.3] 65.5 % [39.6–82.4] 32.2 % [13.8–52.3]
  p value 0.304 0.089 0.290 0.253 0.010 0.020
Act. dis. 10/10 39.7 % [35.7–43.7] 28 % [13.8–44] 32.3 % [28.4–36.3] 37.9 % [33.8–42] 29.4 % [25.5–33.4] 17.5 % [14–21.5]
  9/10 38.4 % [31.6–45.3] 38 % [22.3–53.6] 23.6 % [17.4–29.7] 29.1 % [22.5–35.7] 33.9 % [27.1–40.8] 16.1 % [10.7–22.5]
  8/10 34.3 % [19–50.2] 45.7 % [29.7–60.4] 20 % [6.7–33.3] 22.9 % [8.9–36.8] 30 % [14.4–47.4] 26.1 % [10.1–45.5]
  p value 0.902 0.062 0.107 0.139 0.587 0.578
In vivo No 28.8 % [25.4–32.3] 27.1 % [23.7–30.7] 44 % [40.1–48] 47.7 % [43.7–51.8] 45 % [40.8–49] 26.4 % [22.5–30.4]
T cell Yes 30.7 % [28.8–32.6] 25.9 % [22.5–29.4] 43.4 % [41.3–45.5] 48.8 % [46.7–50.9] 32.9 % [30.9–34.9] 14.6 % [13–16.2]
Depletion p value 0.920 0.448 0.613 0.448 1.0483e-05 1.337e-09
  1. Act. dis. active disease, cGVHD chronic graft-versus-host-disease, CR complete remission, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, RI relapse incidence